Evidence map›Paper›PMID 40308480›Full record

ArticleACS applied engineering materials2025

Development of Low Temperature Activatable Aryl Azide Adhesion Promoters as Versatile Surface Modifiers.

Alexandros A Atzemoglou, Niccolò Bartalucci, Felix Donat, Mark W Tibbitt, Samuele G P Tosatti, Stefan Zürcher

Abstract read
In one paragraph

Article in ACS applied engineering materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alexandros A AtzemoglouSuSoS AG, Lagerstrasse 14, Dübendorf 8600, Switzerland.
Niccolò BartalucciSuSoS AG, Lagerstrasse 14, Dübendorf 8600, Switzerland.
Felix DonatDepartment of Mechanical and Process Engineering, Laboratory of Energy Science and Engineering, ETH Zurich, Zurich 8092, Switzerland.ORCID https://orcid.org/0000-0002-3940-9183
Mark W TibbittDepartment of Mechanical and Process Engineering, Macromolecular Engineering Laboratory, ETH Zurich, Zurich 8092, Switzerland.ORCID https://orcid.org/0000-0002-4917-7187
Samuele G P TosattiSuSoS AG, Lagerstrasse 14, Dübendorf 8600, Switzerland.ORCID https://orcid.org/0000-0001-9950-0205
Stefan ZürcherSuSoS AG, Lagerstrasse 14, Dübendorf 8600, Switzerland.ORCID https://orcid.org/0000-0001-6990-791X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An innovative approach for the immobilization of polymeric films is the use of bifunctional compounds called adhesion promoters, that create a stable chemical "bridge" between materials, allowing for versatile and permanent surface modification. To connect coating materials that lack reactive groups, the "bridge" forming adhesion promoter needs a highly reactive group that can insert in otherwise unreactive chemical bonds. Activatable perfluoro-aryl azides are commonly used to achieve this, with the limitation that their thermal activation is constrained to elevated temperatures-typically far above 100 °C-and photolytic activation is often unfeasible due to geometry or opaque materials. To overcome this limitation, we designed and synthesized three small organic molecules based on substituted aryl azides with the aim of lowering the activation temperature that restricts the use of existing aryl azides. We demonstrate both computationally via density functional theory (DFT) calculations and experimentally that the activation temperature of an aryl azide can be tuned by varying its substituents, giving access to mild activation temperatures (below 100 °C). The most reactive compound was the ο,ο-difluoro substituted

Identifiers

PMID40308480
PMCPMC12038790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.